Showing 3701-3710 of 5910 results for "".
- Y.ora Vision and Eyexora Global Partner with SERI to Advance New MIGS Platform for Glaucomahttps://modernod.com/news/yora-vision-and-eyexora-global-partner-with-seri-to-advance-new-migs-platform-for-glaucoma/2484184/Y.ora Vision, a newly formed ophthalmic medical device company, announced the signing of a licensing agreement between the Singapore Eye Research Institute (SERI) and Eyexora Global to advance a next-generation minimally invasive surgical device for the treatment o
- EssilorLuxottica Acquires RetinAI, Maker of AI and Data Management Technologyhttps://modernod.com/news/essilorluxottica-acquires-retinai-maker-of-ai-and-data-management-technology/2484183/EssilorLuxottica announced it is acquiring Ikerian AG, a Swiss health technology company operating under the RetinAI brand. Financial terms of the deal were not disclosed.
- Avisi Technologies Receives FDA Approval to Study Novel Approach to Glaucoma Treatmenthttps://modernod.com/news/avisi-technologies-receives-fda-approval-to-study-novel-approach-to-glaucoma-treatment/2484182/Avisi Technologies announced that the FDA has approved an investigational device exemption (IDE) for its glaucoma treatment device, VisiPlate. This milestone paves the way for the company’s SAPPHIRE clinical trial, which will evaluate the device in patie
- Iantrek Announces US Commercial Launch of AlloFlo Uveo, First Surgical Treatment Targeting the Uveoscleral Pathwayhttps://modernod.com/news/iantrek-announces-us-commercial-launch-of-alloflo-uveo-first-surgical-treatment-targeting-the-uveoscleral-pathway/2484180/Iantrek announced the official US commercial launch of AlloFlo Uveo, the first surgical treatment specifically designed to target the uveoscleral pathway. This milestone follows Iantrek’s $42 million Se
- SpyGlass Pharma Announces Promising 24-Month Interim Results from First-in-Human Trial of BIM-IOL Systemhttps://modernod.com/news/spyglass-pharma-announces-promising-24-month-interim-results-from-first-in-human-trial-of-bim-iol-system/2484179/SpyGlass Pharma announced interim 24-month data from its first-in-human clinical trial evaluating the Bimatoprost Drug Pad-IOL System (BIM-IOL System). This technology integrates proprietary non-bioerodible drug pads with SpyGlass Pharma’s IOL, designed
- FDA Clears Complement Therapeutics’ IND Application for CTx001 Gene Therapy in GAhttps://modernod.com/news/fda-clears-complement-therapeutics-ind-application-for-ctx001-gene-therapy-in-ga/2484178/Complement Therapeutics has announced that the FDA has cleared its investigational new drug (IND) application for CTx001, the company’s lead gene therapy candidate. The clearance paves the way for the initiation of Opti-GAIN, a phase 1/2 clinic
- PulseSight: New Peer-Reviewed Data Highlighting Transferrin’s Therapeutic Potential for Dry AMDhttps://modernod.com/news/pulsesight-new-peer-reviewed-data-highlighting-transferrins-therapeutic-potential-for-dry-amd/2484176/PulseSight Therapeutics welcomed the publication of new scientific data reinforcing the therapeutic promise of transferrin (Tf) for the treatment of dry age-related macular degeneration (AMD). The study, conducted by
- Celltrion Receives FDA Approval for Eylea Biosimilar Eydenzelthttps://modernod.com/news/celltrion-receives-fda-approval-for-eylea-biosimilar-eydenzelt/2484171/The FDA has approved Celltrion's Eydenzelt (aflibercept-boav), a biosimilar referencing Eylea (aflibercept), for the treatment of wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO)
- Konan Medical Receives CE Marking for ObjectiveFIELD Analyzer (OFA)https://modernod.com/news/konan-medical-receives-ce-marking-for-objectivefield-analyzer-ofa/2484170/Konan Medical USA announced that its objectiveFIELD Analyzer (OFA) has received CE Marking under the European Medical Device Regulation (MDR). The CE Mark enables Konan Medical to offer its next-generation perimetry solution to healthcare providers throug
- AviadoBio and UgeneX Therapeutics Announce Agreement to Advance Gene Therapy for Retinitis Pigmentosahttps://modernod.com/news/aviadobio-and-ugenex-therapeutics-announce-agreement-to-advance-gene-therapy-for-retinitis-pigmentosa/2484165/AviadoBio and UgeneX Therapeutics announced an exclusive option and license agreement for the development and commercialization of UGX-202, an investigational AAV-based gene therapy currently in clinical development for retinitis pigmentosa (RP). The agreement